Skip to main content

Nervgen Pharma Corp(NGEN-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low5.420
Day High5.560
Open:5.500
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Nervgen Pharma Corp

Select a category then submit the form to load news
GlobeNewswire
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
Newsfile
Upcoming Meeting Dates - February 23, 2026
GlobeNewswire
NervGen Pharma to Participate at Upcoming Investor Conferences
GlobeNewswire
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
GlobeNewswire
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
GlobeNewswire
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
GlobeNewswire
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
GlobeNewswire
NervGen Pharma Begins Trading on Nasdaq Today
Newsfile
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Newsfile
NervGen Pharma Announces Proposed Amendment to Warrants
INK Research
Director buying at NervGen Pharma (NGEN)
Company Chart of NGEN
Newsfile
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Newsfile
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
INK Research
Off-market insider buying at NervGen Pharma (NGEN)
Company Chart of NGEN
Newsfile
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Newsfile
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Newsfile
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Newsfile
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
Newsfile
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
Newsfile
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
Newsfile
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Newsfile
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
Newsfile
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
AI-generated - The Globe and Mail
NervGen Pharma: Stocks Overvalued by Analyst Consensus on TSX-V (NGEN)
PR Newswire
Canadian Investment Regulatory Organization Trade Resumption - NGEN
PR Newswire
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Newsfile
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
Newsfile
NervGen Pharma Grants Stock Options
Newsfile
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Newsfile
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Newsfile
NervGen Provides Quarterly "At-The-Market" Equity Program Update
Newsfile
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Profile

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.